MONTREAL, Feb. 27, 2023 /CNW/ - The members of IRICoR's Board of Directors are proud today to announce the appointment of Elizabeth Douville, Ph.D., ICD.D, to the position of President and Chief Executive Officer of the organization. This appointment comes after Dr. Nadine Beauger, Ph.D., MBA, informed the members of the Board of Directors of her decision to leave the position of President and Chief Executive Officer of IRICoR after 14 remarkable years with the organization.
With a very impressive track record, Dr. Elizabeth Douville will bring over 25 years of experience as a venture capitalist in the field of life sciences. She is the founder of AmorChem, a leading early-stage venture capital fund focusing on academic innovation and its translation into start-up biotech companies, and was until just recently its Managing Partner. She has sourced, led and overseen several investments in biotech companies, in promising academic technologies, and has successfully catalyzed the creation and syndication of several spin-off companies, including Inversago Pharma, Corbin Therapeutics, Fairhaven Pharmaceuticals and SemaThera, that have successfully raised capital or partnered with pharmaceutical companies. Since her early debut in the field of venture capital as a Manager for the GeneChem Technologies Venture Fund, Dr. Elizabeth Douville has gone on to raise close to 300 million dollars for different funds over the course of her career and has piloted several investments in both Canada and the United States.
"Elizabeth Douville is a seasoned businesswoman, her reputation precedes her. She is known for her leadership skills, her ability to develop, foster and nurture interpersonal relationships, her strategic and entrepreneurial vision, and her close connections with the academic, industrial and governmental environment. I am delighted with Dr. Douville's appointment and I am convinced that the combination of all those unique attributes will enable her to address the challenges ahead for IRICoR, and in particular, diversifying funding sources, attracting new projects and rallying round our ecosystem's key players. She will be a leading figure within the organization! There is no doubt in my mind that in collaboration with the current team, she will be able to foster the deployment of our actions in order to take IRICoR even further," said Jean-François Leprince, Chairman of IRICoR's Board of Directors.
Dr. Elizabeth Douville also has a keen interest in governance. In 2020, she received a Certificate in Leadership and Executive Skills from the Leadership Institute and took part in the prestigious Business Development Bank of Canada's GP Academy program. More recently, she was awarded the ICD.D. designation by the Institute of Corporate Directors. Her highly committed and active participation in the life sciences ecosystem has led her to serve on the Boards of several companies and not-for-profit organizations. She is Chair of Genome Canada, a Member of the Canada Foundation for Innovation and a member of the Research Canada Policy Engagement Committee. She is also the vice chair of the Emerging Company Advisory Board of BIOTECanada and an active member of the Board of Directors of Corbin Therapeutics Inc. and SemaThera Inc.
"I am honoured by this appointment and I thank the members of IRICoR's Board of Directors for putting their trust in me. I will be devoted to continuing the work undertaken, by putting my expertise and my vision to good use in the success and visibility of the IRICoR solution. I am very excited about joining the team in place and contributing in a tangible way to the development and maturation of promising academic assets and to their exit strategies, by creating investment opportunities for foreign capital through co-development partnerships with the biopharmaceutical industry, and by stimulating the growth of entrepreneurial activities in life sciences in Canada through the creation of spin-off companies," says Elizabeth Douville.
Also wanting to highlight the work done by Dr. Nadine Beauger at IRICoR since 2009, Jean-François Leprince added: "I would like to thank Dr. Nadine Beauger for her involvement and her longstanding commitment. Dr. Beauger has distinguished herself in many ways, including through her leadership and her outstanding contribution over the course of her mandate to extend IRICoR's mark across Quebec and the rest of Canada. After fourteen years, we are very grateful to her and we wish her every success with her next challenges."
Designated as a Centre of Excellence in Research and Commercialization (CECR) by the Canadian government and based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, IRICoR is a pan-Canadian leader in the de-risking of early-stage assets in the field of drug discovery. IRICoR's mandate is to accelerate the discovery, development, and commercialization of novel therapies in cancer and rare diseases. Since 2008, IRICoR has been successfully investing in and supporting selected high-value projects in order to rapidly translate early-stage innovation into potential new therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR seamlessly combines its business-related expertise with access to industry-level drug discovery capabilities, providing selected academic and industry projects with access to its network of experts and cutting-edge infrastructure, including one of the largest academia-based drug discovery unit in Canada. IRICoR's major funding sources include the federal CECR Program, the Ministère de l'Économie et de l'Innovation du Québec (MEI), and collaborative partnerships with the biopharmaceutical industry.
Related Links
SOURCE IRICOR
Noémie Desbois Mackenzie, Communications Director, IRICoR, 514 475-7682, [email protected]
Share this article